Loading...
XASE
PLX
Market cap143mUSD
Jul 11, Last price  
1.41
1D
-4.73%
1Q
-41.49%
Jan 2017
-68.31%
IPO
-98.28%
Name

Protalix Biotherapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
0.04
Div Yield, %
—
Shrs. gr., 5y
40.44%
Rev. gr., 5y
-0.48%
Revenues
53m
-18.47%
0150,00000388,0006,642,0008,386,00034,424,00011,513,00015,160,0004,364,0009,199,00019,242,00034,240,00054,693,00062,898,00038,350,00047,638,00065,494,00053,399,000
Net income
3m
-64.73%
-74,931-9,390,000-22,481,000-22,414,000-31,440,000-28,998,000-36,529,000-11,618,000-27,790,000-29,943,00058,037,000-29,365,000-85,276,000-26,457,000-26,242,000-14,892,000-33,985,000-14,927,0008,312,0002,932,000
CFO
9m
P
-72,475-5,091,000-10,449,000-16,015,00044,452,000-38,464,000-23,570,000635,000-30,653,000-29,281,000-24,284,000-32,098,000-9,994,000-7,742,000-19,358,000-26,106,000-10,285,000-25,000,000-1,318,0008,674,000
Earnings
Aug 12, 2025

Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
URL
https://protalix.com/
IPO date
Sep 06, 2010
Employees
193
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
53,399
-18.47%
65,494
37.48%
47,638
24.22%
Cost of revenue
49,482
40,075
60,652
Unusual Expense (Income)
NOPBT
3,917
25,419
(13,014)
NOPBT Margin
7.34%
38.81%
Operating Taxes
1,222
254
530
Tax Rate
31.20%
1.00%
NOPAT
2,695
25,165
(13,544)
Net income
2,932
-64.73%
8,312
-155.68%
(14,927)
-56.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,626
23,954
8,236
BB yield
Debt
Debt current
1,500
23,069
1,118
Long-term debt
9,552
10,651
37,643
Deferred revenue
Other long-term liabilities
559
714
1,642
Net debt
(23,778)
(10,840)
16,581
Cash flow
Cash from operating activities
8,674
(1,318)
(25,000)
CAPEX
(1,282)
(1,149)
(628)
Cash from investing activities
4,221
(16,711)
(5,035)
Cash from financing activities
(16,794)
24,666
8,238
FCF
4,740
18,136
(13,262)
Balance
Cash
34,830
44,560
22,180
Long term investments
Excess cash
32,160
41,285
19,798
Stockholders' equity
(378,317)
(381,476)
(389,807)
Invested Capital
427,613
443,449
413,753
ROIC
0.62%
5.87%
ROCE
7.95%
41.02%
EV
Common stock shares outstanding
81,057
82,424
48,472
Price
Market cap
EV
EBITDA
5,221
26,610
(11,928)
EV/EBITDA
Interest
1,062
3,180
2,529
Interest/NOPBT
27.11%
12.51%